Kanyini Audit Study - XYZ Health Service Feedback Report

| **XYZ Health Service**		**National**	
Records audited	200	Records audited	1165
Mean age	42.9	Mean age	41.1
% Male	43.5%	% Male	40.5%
% Female	56.5%	% Female	59.5%

Recorded Past History

Comment:
These specific recorded conditions were looked for in this audit. The results do not reflect all recorded conditions found in the case record

Risk Factor Recording

### Smoking status

Body Mass Index

Albuminuria

Albuminuria
(Data available: National n=338, XYZ Health Service n=52)

Chronic Kidney Disease

Chronic Kidney Disease
(Data Available: National n=669, XYZ Health Service n=131)

1

Summary of risk factor recording

Risk factor recorded	XYZ Health (n=39) %	National (n=1165) %
Blood Pressure	98.5%	90.2
Blood glucose	91.5%	78.9
Smoking status	80.0%	71.4
Lipids	67.0%	58.9
eGFR	65.5%	57.4
Body Mass Index (BMI)	59%	55.7
Albumin Creatine Ratio (ACR)	26.0%	29.0
ACR and eGFR for at risk CKD*	32.5%	31.8

* n=151 for XYZ, n=851 for National

Comment:
People 'at risk of Chronic Kidney Disease (CKD)' is based on Kidney Health Australia guidelines and includes any one of the following:
- *Age>50 years*
- *BP >140/90 mmHg*
- *Diabetes*
- *Current smoker*
- *BMI≥30 kg/m^2*

Diabetes Profile

Comment:
Only 36 of 55 people with diabetes had sufficient data to record albuminuria

Cardiovascular risk profile

*Sufficient data were only available for 82 of 154 people in the sample aged over 30 years old and therefore results should be interpreted with caution

Comment:

Cardiovascular risk is calculated using the Framingham based New Zealand Cardiovascular Guidelines. This includes a 5% addition to the risk calculation for Indigenous populations.

The risk assessment algorithm is not validated for under 30 year olds

Care provided

Comment:

Lifestyle assessment was recorded as present if there was any evidence in the clinical record of discussion with the client about smoking, nutrition, physical activity or alcohol in the past 2 years

Enhanced Primary Care Items

EPC Medicare Items- XYZ Health Service
(For item 710 n=156, 704 n=44, 721-725 n=66)

Comment:

EPC items were recorded as complete if there was evidence in the record of a complete assessment and/or evidence of billing for that item. If there was evidence of an unclaimed or partially filled assessment it was recorded as incomplete.

EPC Medicare Items- National
(For item 710 n=940, 704 n=225, 721-725 n=322)

Cardiovascular medicines prescribed

Medications	Total Sample		Clients with Diabetes*		Clients with CVD*	
	XYZ n=200	National n=1165	XYZ n=55	National n=249	XYZ n=27	National n=101
	%	%	%	%	%	%
Blood pressure lowering	30%	28	66%	76	82%	81
Cholesterol lowering	27%	22	69%	64	74%	77
Antiplatelet medication	18%	21	44%	62	63%	74
BP + Statin + Antiplatelet	11%	14	29%	42	44%	58

Blood pressure management- prescribing patterns

XYZ Health Service- Blood pressure Management NHF guidelines*

Total sample n=200

On treatment n=59 (29%)

Not on treatment n=141 (71%)

At target
n=30
(51% of those on treatment)

Not at target
n=29
(49% of those on treatment)

Treatment indicated
n=25
(18% of those not on treatment)

Treatment not indicated
n=113
(80% of those not on treatment)

Unknown
n=3
(2% of those not on treatment)

Overall Treatment /Prescribing Gap
n=54
(27.0% of the total sample)

* Target BP <130 Systolic Diabetes, <140 for all others

National- Blood pressure management NHF guidelines*

Total sample n=1165

On treatment n=329 (28%)

Not on treatment n=836 (72%)

Unknown
n=1
(0.3% of those on treatment)

At target
n=203
(62% of those on treatment)

Not at target
n=125
(38% of those on treatment)

Treatment indicated
n=90
(11% of those not on treatment)

Treatment not indicated
n=636
(76% of those not on treatment)

Unknown
n=110
(13% of those not on treatment)

Overall Treatment /Prescribing Gap
n=215
(18% of the total sample)

* Target BP <130 Systolic Diabetes, <140 for all others

Comment:

Treatment thresholds were based on the average of the two most recent systolic blood pressure recorded values

Treatment indications and target values were measured against the National Heart Foundation guidelines

Lipid management- prescribing patterns

XYZ Health Service- Lipid management PBS2007 guidelines*

Total sample
n=200

On treatment
n=54 (27%)

Not on treatment
n=146 (73%)

Unknown
n=5
(9% of those on treatment)

At target*
n=12
(22% of those on treatment)

Not at target
n=37
(69% of those on treatment)

Treatment indicated*
n=30
(21% of those not on treatment)

Treatment not indicated
n=55
(38% of those not on treatment)

Unknown
n=61
(42% of those not on treatment)

Overall Treatment / Prescribing Gap
n=67
(34% of the total sample)

*PBS Indications for treatment
- Diabetes or CVD at any level
- Total Cholesterol>6.5mmol
- Total Cholesterol>5.5 and HDL<1.0

*Treatment target <4mmol/L

National findings- Lipid management PBS2007 guidelines*

Total sample
n=1165

On treatment
n=256 (22%)

Not on treatment
n=909 (78%)

Unknown
n=27
(11% of those on treatment)

At target*
n=51
(20% of those on treatment)

Not at target
n=178
(70% of those on treatment)

Treatment indicated*
n=145
(16% of those not on treatment)

Treatment not indicated
n=311
(34% of those not on treatment)

Unknown
n=453
(50% of those not on treatment)

Overall Treatment /Prescribing Gap
n=323
(28% of the total sample)

*PBS Indications for treatment
- Diabetes or CVD at any level
- Total Cholesterol>6.5mmol
- Total Cholesterol>5.5 and HDL<1.0

*Treatment target <4mmol/L

Comment:

Treatment thresholds were based on the most recent cholesterol results.

Treatment indications and target values were measured against the 2007 Pharmaceutical Benefits Scheme indications for Aboriginal and Torres Strait Islander people.